ERAS and breast carcinoma: These somatic mutations are found predominantly in the ERα ligand-binding domain (LBD) and the ERα mutations Y537S or D538G, that are present in up to 40% of endocrine therapy-resistant metastatic breast cancer patients and are a major mechanism of acquired resistance to hormonal therapies [82,87,88,89,90,91].